mhb018a
Recombinant proteinexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
3
Phase 4
0
Earliest trial started Jul 22, 2025 (NCT06989918)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 3 Sponsor(trial)
Indications
Studied for
Mechanism of action
IGF1R inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07262476 | Phase 3 | Jan 31, 2026 | Minghui Pharmaceutical Pty Ltd |
| NCT07257185 | Phase 3 | Dec 31, 2025 | Minghui Pharmaceutical Pty Ltd |
| NCT06989918 | Phase 3 | Jul 22, 2025 | Minghui Pharmaceutical Pty Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Minghui Pharmaceutical Pty Ltd | For profit | 3 | 3 | 1 | 2025 |
1 organizations
Page 1 / 1